NVS

Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates and MRI lesion activity versus teriflunomide in the REMODEL-1 and REMODEL-2 studies. The company said global regulatory

Novartis discussed results from the REMODEL trial, which tested remibrutinib in patients with relapsing multiple sclerosis. The company presented data on the drug’s effectiveness and safety in this patient group.

The article is a slideshow covering the REMODEL trial results for remibrutinib in relapsing multiple sclerosis.

Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹˒²MRI disease activity significantly reduced with remibrutinib vs.

Novartis announced that remibrutinib reduced the annualized relapse rate by 35.2% in the REMODEL-1 study and by 31.2% in REMODEL-2, both Phase III trials for relapsing multiple sclerosis. The company highlighted robust safety and comprehensive disease control.

Novartis reported that Kisqali, from its Phase III NATALEE study, reduces the risk of death by about 20% in patients with Stage II and III HR+/HER2- early breast cancer.

Novartis shares may trade below fair value after the company received Cosentyx approval for polymyalgia rheumatica in Europe, potentially boosting earnings support.

Novartis received European Commission approval for Cosentyx to treat polymyalgia rheumatica in adults, making it the first IL‑17A inhibitor cleared in Europe for this condition.